Draft Guidance for Industry; Availability: Chronic Hepatitis C Virus Infection; Developing Direct-Acting Antiviral Agents forTreatment
Document ID: FDA-2010-D-0462-0001
Comments
Total: 12
-
ELPA (European Liver Patient Association) - Comment
Posted : 10/05/2010 ID ：FDA-2010-D-0462-0003 Agency : FDA -
Nov 15,2010 11:59 PM ET
-
Merck & Co, Inc. - Comment
Posted : 11/18/2010 ID ：FDA-2010-D-0462-0004 Agency : FDA -
Nov 15,2010 11:59 PM ET
-
Boehringer Ingelheim Pharmaceuticals, Inc. - Comment
Posted : 11/18/2010 ID ：FDA-2010-D-0462-0005 Agency : FDA -
Nov 15,2010 11:59 PM ET
-
Novartis - Comment
Posted : 11/18/2010 ID ：FDA-2010-D-0462-0006 Agency : FDA -
Nov 15,2010 11:59 PM ET
-
GlaxoSmithKline - Comment
Posted : 11/18/2010 ID ：FDA-2010-D-0462-0007 Agency : FDA -
Nov 15,2010 11:59 PM ET
-
Merck & Company - Comment
Posted : 11/18/2010 ID ：FDA-2010-D-0462-0008 Agency : FDA -
Nov 15,2010 11:59 PM ET
-
Hoffmann-La Roche Inc and Genentech Inc - Comment
Posted : 11/18/2010 ID ：FDA-2010-D-0462-0009 Agency : FDA -
Nov 15,2010 11:59 PM ET
-
Gilead Sciences Inc. - Comment
Posted : 11/18/2010 ID ：FDA-2010-D-0462-0010 Agency : FDA -
Nov 15,2010 11:59 PM ET
-
People with Bleeding Disorders and HCV - Comment
Posted : 11/18/2010 ID ：FDA-2010-D-0462-0011 Agency : FDA -
Nov 15,2010 11:59 PM ET
-
Abbott - Comment
Posted : 11/18/2010 ID ：FDA-2010-D-0462-0012 Agency : FDA -
Nov 15,2010 11:59 PM ET
-
Hoffmann-La Roche, Inc. - Comment
Posted : 12/20/2010 ID ：FDA-2010-D-0462-0013 Agency : FDA -
Nov 15,2010 11:59 PM ET
-
Presidio Pharmaceuticals, Inc. - Comment
Posted : 12/20/2010 ID ：FDA-2010-D-0462-0014 Agency : FDA -
Nov 15,2010 11:59 PM ET